All filters
Slidesets
Anti-HBV potential of PD-1/PD-L1 blockade in chronic HBV infection | Daniel Verdon
Presented at:
International Workshop on HBV Cure 2018
Slidesets
Rationale for Modulating Adaptive Immunity: Therapeutic Vaccination, Checkpoint Inhibitor and others | Robert Thimme
Presented at:
International Workshop on HBV Cure 2018
Slidesets
Clinical progress of the entry inhibitor Myrcludex B | Stephan Urban
Presented at:
International Workshop on HBV Cure 2018
Slidesets
Rationale for different Virological Targets in HBV | Stephen Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)
Presented at:
International Workshop on HBV Cure 2018
Slidesets
Clinical update on reducing HBV virus and antigen production using RNAi | Bruce Given
Presented at:
International Workshop on HBV Cure 2018
Slidesets
Clinical update, antiviral effect and mode of action of capsid assembly modulators | Jeysen Yogaratnam
Presented at:
International Workshop on HBV Cure 2018
Slidesets
Establishing functional control of HBV and HDV infection with REP 2139-based combination therapy | Andrew Vaillant
Presented at:
International Workshop on HBV Cure 2018
Slidesets
Targeting HBV Core Protein to Clear Infection and Achieve Higher Cure Rates | Richard Colonno
Presented at:
International Workshop on HBV Cure 2018
Slidesets
What is the cure rate with current therapies? | Harry Janssen, MD, PhD
Presented at:
International Workshop on HBV Cure 2018
Slidesets
Immune reconstitution with current available antiviral therapies: a baseline to gauge new immunotherapies | Andre Boonstra
Presented at:
International Workshop on HBV Cure 2018
Slidesets
Stopping Nucleos(t)ide Analogues: When is it beneficial, when is it dangerous? | Thomas Berg, MD
Presented at:
International Workshop on HBV Cure 2018
Slidesets
Will HBsAg depletion restore HBV specific immunity? | Adam Gehring, PhD
Presented at:
International Workshop on HBV Cure 2018
Slidesets
What are the pros and cons of HBsAg loss as the endpoint for treatment? | Jordan Feld, MD, MPH
Presented at:
International Workshop on HBV Cure 2018
Slidesets
Antiviral effect of the RIG-I agonist, Inarigavir | Nezam Afdahl
Presented at:
International Workshop on HBV Cure 2018
Slidesets
Rationale for modulating innate immunity: TLR, RIG- and others | Mala Maini, MD, PhD
Presented at:
International Workshop on HBV Cure 2018
Slidesets
Combination treatment of a TLR7 agonist RO7020531 and a core protein allosteric modulator RO7049389 achieved sustainable viral load suppression and HBsAg loss in an AAV-HBV mouse model | Yonghong Zhu
Presented at:
International Workshop on HBV Cure 2018
Slidesets
Innate activation with Inactivated parapox viruses for HBV therapy - AIC649 | Daniela Paulsen
Presented at:
International Workshop on HBV Cure 2018
Videos
Stopping Nucleos(t)ide Analogues: When is it beneficial, when is it dangerous? | Thomas Berg, MD
Presented at:
International Workshop on HBV Cure 2018
Videos
Will HBsAg depletion restore HBV specific immunity? | Adam Gehring, PhD
Presented at:
International Workshop on HBV Cure 2018
Videos
What are the pros and cons of HBsAg loss as the endpoint for treatment? | Jordan Feld, MD, MPH
Presented at:
International Workshop on HBV Cure 2018
Videos
Anti-HBV potential of PD-1/PD-L1 blockade in chronic HBV infection | Daniel Verdon
Presented at:
International Workshop on HBV Cure 2018
Videos
Innate activation with Inactivated parapox viruses for HBV therapy - AIC649 | Daniela Paulsen
Presented at:
International Workshop on HBV Cure 2018